LIMITED EVIDENCE ON IMAGING FOR DETECTING PROSTATE CANCER: A SYSTEMATIC REVIEW
Main
Arizal Abdulloh*
This research aims to assess the diagnostic accuracy of imaging technology in detecting prostate cancer in patients with high PSA levels or suspicious findings in clinical examinations. The method involved searching for articles from the Medline, EMBASE, and Cochrane databases from 2011 to 2023. The selected articles used predefined inclusion criteria, and the risk of bias in individual studies was assessed using QUADAS-2. The abstracts and full texts were independently evaluated by the authors to assess the sensitivity and specificity of the imaging. The selection process followed the PRISMA 2020 guidelines. The literature search yielded 5421 abstracts, which were independently reviewed by the authors. Out of this number, 5401 abstracts were excluded due to irrelevance to the research title and abstract. Subsequently, a full review was conducted on 20 articles to assess their quality. Among the 20 articles, 14 studies were excluded because they were not original research, the PICO was not relevant, or the methods and populations used were not adequately described. Finally, six studies were included in this research, with four studies concerning MRI and two studies involving transrectal ultrasound with Doppler. Overall, the research findings indicate that the current number of imaging studies with adequate scientific quality is still limited to recommend their use beyond clinical trials for patients with high PSA levels or suspicious findings in clinical examinations. Therefore, further research is needed to strengthen and generalize these findings before imaging technology can be widely used as a diagnostic method for prostate cancer in this patient group.
American Cancer Society. (2007). Global Cancer Facts and Figures 2007. Cancer.
Barentsz, J. O., Richenberg, J., Clements, R., Choyke, P., Verma, S., Villeirs, G., Rouviere, O., Logager, V., & Fütterer, J. J. (2012). ESUR prostate MR guidelines 2012. European Radiology, 22(4). https://doi.org/10.1007/s00330-011-2377-y
Cosma, I., Tennstedt-Schenk, C., Winzler, S., Psychogios, M. N., Pfeil, A., Teichgraeber, U., Malich, A., & Papageorgiou, I. (2019). The role of gadolinium in magnetic resonance imaging for early prostate cancer diagnosis: A diagnostic accuracy study. PLoS ONE, 14(12), 1–16. https://doi.org/10.1371/journal.pone.0227031
Dickinson, L., Ahmed, H. U., Allen, C., Barentsz, J. O., Carey, B., Futterer, J. J., Heijmink, S. W., Hoskin, P. J., Kirkham, A., Padhani, A. R., Persad, R., Puech, P., Punwani, S., Sohaib, A. S., Tombal, B., Villers, A., Van Der Meulen, J., & Emberton, M. (2011). Magnetic resonance imaging for the detection, localisation, and characterisation of prostate cancer: Recommendations from a European consensus meeting. European Urology, 59(4). https://doi.org/10.1016/j.eururo.2010.12.009
Djavan, B., Ravery, V., Zlotta, A., Dobronski, P., Dobrovits, M., Fakhari, M., Seitz, C., Susani, M., Borkowski, A., Boccon-Gibod, L., Schulman, C. C., & Marberger, M. (2001). Prospective evaluation of prostate cancer detected on biopsies 1, 2, 3 and 4: When should we stop? Journal of Urology, 166(5). https://doi.org/10.1016/s0022-5347(05)65652-2
Drost, F.-J. H., Osses, D. F., Nieboer, D., Steyerberg, E. W., Bangma, C. H., Roobol, M. J., & Schoots, I. G. (2019). Prostate MRI, with or without MRI-targeted biopsy, and systematic biopsy for detecting prostate cancer. Cochrane Database of Systematic Reviews, 2019(4). https://doi.org/10.1002/14651858.cd012663.pub2
Girometti, R., Bazzocchi, M., Como, G., Brondani, G., Del Pin, M., Frea, B., Martinez, G., & Zuiani, C. (2012). Negative predictive value for cancer in patients with “gray-Zone” PSA level and prior negative biopsy: Preliminary results with multiparametric 3.0 tesla MR. Journal of Magnetic Resonance Imaging, 36(4). https://doi.org/10.1002/jmri.23703
Gupta, I., Freid, B., Masarapu, V., Machado, P., Trabulsi, E., Wallace, K., Halpern, E., & Forsberg, F. (2020). Transrectal Subharmonic Ultrasound Imaging for Prostate Cancer Detection. Urology, 138, 106–112. https://doi.org/10.1016/j.urology.2019.12.025
Haider, M. A., Yao, X., Loblaw, A., & Finelli, A. (2016). Multiparametric Magnetic Resonance Imaging in the Diagnosis of Prostate Cancer: A Systematic Review. Clinical Oncology, 28(9), 550–567. https://doi.org/10.1016/j.clon.2016.05.003
Ho, C. C. K., Khor, T. W., Singam, P., Goh, E. H., Tan, G. H., Bahadzor, B., & Zulkifli, M. Z. (2012). Evaluation of Power Doppler Ultrasonography for prostate biopsy in men with elevated serum prostate specific antigen levels. Clinica Terapeutica, 163(3).
Oerther, B., Schmucker, C., Schwarzer, G., Schoots, I., Sigle, A., Gratzke, C., Bamberg, F., & Benndorf, M. (2022). Living systematic review and meta-analysis of the prostate MRI diagnostic test with Prostate Imaging Reporting and Data System (PI-RADS) assessment for the detection of prostate cancer: study protocol. BMJ Open, 12(10), 1–7. https://doi.org/10.1136/bmjopen-2022-066327
Otti, V. C., Miller, C., Powell, R. J., Thomas, R. M., & McGrath, J. S. (2019). The diagnostic accuracy of multiparametric magnetic resonance imaging before biopsy in the detection of prostate cancer. In BJU International (Vol. 123, Issue 1). https://doi.org/10.1111/bju.14420
Raaijmakers, R., Kirkels, W. J., Roobol, M. J., Wildhagen, M. F., & Schrder, F. H. (2002). Complication rates and risk factors of 5802 transrectal ultrasound-guided sextant biopsies of the prostate within a population-based screening program. Urology, 60(5). https://doi.org/10.1016/S0090-4295(02)01958-1
Schröder, F. H., Hugosson, J., Roobol, M. J., Tammela, T. L. J., Ciatto, S., Nelen, V., Kwiatkowski, M., Lujan, M., Lilja, H., Zappa, M., Denis, L. J., Recker, F., Berenguer, A., Määttänen, L., Bangma, C. H., Aus, G., Villers, A., Rebillard, X., van der Kwast, T., … Auvinen, A. (2009). Screening and Prostate-Cancer Mortality in a Randomized European Study. New England Journal of Medicine, 360(13). https://doi.org/10.1056/nejmoa0810084
Stamey, T. A., Yang, N., Hay, A. R., McNeal, J. E., Freiha, F. S., & Redwine, E. (1987). Prostate-Specific Antigen as a Serum Marker for Adenocarcinoma of the Prostate. New England Journal of Medicine, 317(15). https://doi.org/10.1056/nejm198710083171501
Tamada, T., Sone, T., Higashi, H., Jo, Y., Yamamoto, A., Kanki, A., & Ito, K. (2011). Prostate cancer detection in patients with total serum prostate-specific antigen levels of 4-10 ng/mL: Diagnostic efficacy of diffusion-weighted imaging, dynamic contrast-enhanced MRI, and T2-weighted imaging. American Journal of Roentgenology, 197(3). https://doi.org/10.2214/AJR.10.5923
Vilanova, J. C., Barceló-Vidal, C., Comet, J., Boada, M., Barceló, J., Ferrer, J., & Albanell, J. (2011). Usefulness of prebiopsy multifunctional and morphologic MRI combined with free-to-total prostate-specific antigen ratio in the detection of prostate cancer. American Journal of Roentgenology, 196(6). https://doi.org/10.2214/AJR.10.5700
Whiting, P. F., Rutjes, A. W. S., Westwood, M. E., Mallett, S., Deeks, J. J., Reitsma, J. B., Leeflang, M. M. G., Sterne, J. A. C., & Bossuyt, P. M. M. (2011). Quadas-2: A revised tool for the quality assessment of diagnostic accuracy studies. In Annals of Internal Medicine (Vol. 155, Issue 8). https://doi.org/10.7326/0003-4819-155-8-201110180-00009
Williams, I. S. C., McVey, A., Perera, S., O’Brien, J. S., Kostos, L., Chen, K., Siva, S., Azad, A. A., Murphy, D. G., Kasivisvanathan, V., Lawrentschuk, N., & Frydenberg, M. (2022). Modern paradigms for prostate cancer detection and management. Medical Journal of Australia, 217(8), 424–433. https://doi.org/10.5694/mja2.51722
